SciSparc Ltd. - Ordinary Shares (SPRC)
SPRC moved a median of -1.32% 30 minutes after news, and -2.73% by the close. How SPRC actually reacts to news — the realized, point-in-time move the market made, measured across 306 labeled events over the last three years with zero look-ahead.
SPRC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.46% | 33% | 297 |
| 30-min | -1.32% | 35% | 305 |
| 60-min | -1.37% | 35% | 306 |
| to close | -2.73% | 36% | 306 |
| Middle 50% of SPRC reactions | -3.39% to +1.02% |
|---|---|
| Median reaction (30-min) | -1.32% |
| Measured reactions | 306 |
Half of all SciSparc Ltd. - Ordinary Shares news events land between -3.39% and +1.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SPRC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SPRC's baseline. Nothing else.
Recent SPRC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications | Press release | GlobeNewswire | -0.01% | -14.11% | |
| Form 6-K SciSparc Ltd. For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | +0.29% | -53.71% | |
| SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies | Press release | GlobeNewswire | +1.91% | -52.38% | |
| Form 6-K SciSparc Ltd. For: Oct 07 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +5.46% | |
| SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture | Press release | GlobeNewswire | +0.00% | +5.46% | |
| Form 6-K SciSparc Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | — | -0.66% | |
| Form 6-K SciSparc Ltd. For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | +2.05% | +10.45% | |
| SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations | Press release | GlobeNewswire | +1.93% | +7.28% | |
| Form 6-K SciSparc Ltd. For: Sep 02 | SEC filing · Form 6-K | SEC EDGAR | -1.23% | -9.68% | |
| SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies | Press release | GlobeNewswire | -4.58% | +0.86% | |
| Form EFFECT SciSparc Ltd. | SEC filing · Form EFFECT | SEC EDGAR | -2.25% | -8.84% | |
| SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial | Press release | GlobeNewswire | -2.25% | -8.84% | |
| Form 6-K SciSparc Ltd. For: Aug 26 | SEC filing · Form 6-K | SEC EDGAR | — | -1.78% | |
| SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board | Press release | GlobeNewswire | +0.30% | +0.90% | |
| Form 6-K SciSparc Ltd. For: Aug 24 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.19% | |
| SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation | Press release | GlobeNewswire | +0.00% | -1.19% | |
| Form 20-F/A SciSparc Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.15% | +5.38% | |
| Form F-3/A SciSparc Ltd. | SEC filing · Form F-3 | SEC EDGAR | -2.04% | -3.43% | |
| Form 6-K SciSparc Ltd. For: Aug 18 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | +5.38% | |
| SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million | Press release | GlobeNewswire | — | -1.96% | |
| Form 6-K SciSparc Ltd. For: Aug 12 | SEC filing · Form 6-K | SEC EDGAR | -3.12% | +2.96% | |
| SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination | Press release | GlobeNewswire | -3.12% | +2.96% | |
| Form 6-K SciSparc Ltd. For: Aug 05 | SEC filing · Form 6-K | SEC EDGAR | -1.73% | -0.43% | |
| SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome | Press release | GlobeNewswire | -1.73% | -0.43% | |
| Form 6-K SciSparc Ltd. For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | -5.68% | -5.95% | |
| SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics | Press release | GlobeNewswire | -5.68% | -5.95% | |
| Form 6-K SciSparc Ltd. For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | -0.80% | +44.52% | |
| SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company | Press release | GlobeNewswire | -0.80% | +44.52% | |
| SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity | Press release | GlobeNewswire | +2.59% | +3.73% | |
| Form 6-K SciSparc Ltd. For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +12.84% | |
| SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome | Press release | GlobeNewswire | +0.92% | +13.16% | |
| Form 6-K SciSparc Ltd. For: Jun 04 | SEC filing · Form 6-K | SEC EDGAR | -3.37% | -15.46% | |
| SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum | Press release | GlobeNewswire | -3.37% | -15.46% | |
| Form 6-K SciSparc Ltd. For: May 29 | SEC filing · Form 6-K | SEC EDGAR | -3.00% | -1.90% | |
| SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | Press release | GlobeNewswire | -5.32% | -19.77% | |
| Form 6-K SciSparc Ltd. For: May 11 | SEC filing · Form 6-K | SEC EDGAR | +1.43% | -3.96% | |
| Form 20-F SciSparc Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -8.98% | -0.34% | |
| Form 6-K SciSparc Ltd. For: Mar 16 | SEC filing · Form 6-K | SEC EDGAR | +1.17% | +8.20% | |
| SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy | Press release | GlobeNewswire | -2.06% | -0.92% | |
| Form 6-K SciSparc Ltd. For: Mar 12 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +5.83% | |
| SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease | Press release | GlobeNewswire | +4.59% | +20.97% | |
| SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails | Press release | GlobeNewswire | -5.09% | -26.91% | |
| Form 6-K SciSparc Ltd. For: Mar 02 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.08% | |
| SciSparc Announces 1-for-9 Reverse Share Split | Press release | GlobeNewswire | +0.00% | +2.08% | |
| Form 6-K SciSparc Ltd. For: Feb 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.97% | |
| Form F-3 SciSparc Ltd. | SEC filing · Form F-3 | SEC EDGAR | +0.00% | -4.97% | |
| Form EFFECT SciSparc Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +6.64% | +0.86% | |
| Form 6-K SciSparc Ltd. For: Feb 12 | SEC filing · Form 6-K | SEC EDGAR | +6.64% | +0.86% | |
| Form 6-K SciSparc Ltd. For: Feb 04 | SEC filing · Form 6-K | SEC EDGAR | -1.80% | -7.54% | |
| Form F-3 SciSparc Ltd. | SEC filing · Form F-3 | SEC EDGAR | +1.11% | -9.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SPRC section they belong to.
Where else SPRC is measured.
SPRC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is SciSparc Ltd. - Ordinary Shares's median reaction calculated?
Every labeled SPRC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 306 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of SPRC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SPRC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.